Finally, bevacizumab, a humanised anti-VEGF-A monoclonal antibody, has been tested in patients with biliary tract cancer, in combination with gemcitabine and oxaiplatin, in a phase II trial. Here, VEGFA is linked to biliary tract neoplasm.